# Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

> **NCT02207257** · PHASE2 · COMPLETED · sponsor: **Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Anticoagulation Reversal

## Interventions

- **DRUG:** PER977
- **DRUG:** Placebo
- **DRUG:** Edoxaban

## Key facts

- **NCT ID:** NCT02207257
- **Lead sponsor:** Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-09
- **Final completion:** 2015-11
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2020-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207257, "Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02207257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*